MEP14508A - Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels - Google Patents

Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Info

Publication number
MEP14508A
MEP14508A MEP-145/08A MEP14508A MEP14508A ME P14508 A MEP14508 A ME P14508A ME P14508 A MEP14508 A ME P14508A ME P14508 A MEP14508 A ME P14508A
Authority
ME
Montenegro
Prior art keywords
pharmaceutical compositions
testosterone levels
serum testosterone
methods
reliable achievement
Prior art date
Application number
MEP-145/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Doris Huebler
Sabine Fricke
Jan-Peter Ingwersen
Wilhelm Kuhnz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP14508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP14508A publication Critical patent/MEP14508A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MEP-145/08A 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels MEP14508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
PCT/IB2004/000716 WO2004080383A2 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (1)

Publication Number Publication Date
MEP14508A true MEP14508A (en) 2010-06-10

Family

ID=32748728

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-145/08A MEP14508A (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
MEP-2008-145A ME00149B (me) 2003-03-14 2004-03-15 Postupci i farmaceutski sastavi za pouzdano postizanje prihvatljivih nivoa seruma testosterona

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-145A ME00149B (me) 2003-03-14 2004-03-15 Postupci i farmaceutski sastavi za pouzdano postizanje prihvatljivih nivoa seruma testosterona

Country Status (39)

Country Link
US (2) US7718640B2 (is)
EP (2) EP1457208B9 (is)
JP (1) JP4680891B2 (is)
KR (2) KR100882378B1 (is)
CN (2) CN101884639A (is)
AR (1) AR043603A1 (is)
AT (1) ATE336251T1 (is)
AU (1) AU2004218893B2 (is)
BR (2) BR122017008910A8 (is)
CA (1) CA2518910C (is)
CL (1) CL2004000527A1 (is)
CO (1) CO5700724A2 (is)
CR (1) CR7999A (is)
CY (1) CY1105794T1 (is)
DE (1) DE602004001893T2 (is)
DK (1) DK1457208T3 (is)
EA (1) EA011568B1 (is)
EC (1) ECSP056095A (is)
ES (1) ES2271772T3 (is)
HR (1) HRP20050781B1 (is)
IL (1) IL170473A (is)
IS (1) IS2565B (is)
JO (1) JO2505B1 (is)
ME (2) MEP14508A (is)
MX (1) MXPA04002395A (is)
NO (1) NO335179B1 (is)
NZ (1) NZ542321A (is)
PE (1) PE20041065A1 (is)
PL (1) PL1457208T3 (is)
PT (1) PT1457208E (is)
RS (1) RS51537B (is)
RU (2) RU2354381C2 (is)
SA (1) SA04250040B1 (is)
SI (1) SI1457208T1 (is)
TW (1) TWI345976B (is)
UA (1) UA82510C2 (is)
UY (1) UY28231A1 (is)
WO (1) WO2004080383A2 (is)
ZA (2) ZA200508313B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
DK2985026T3 (da) 2005-04-15 2022-10-31 Clarus Therapeutics Inc Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
CN104487114A (zh) * 2012-04-06 2015-04-01 安塔雷斯药品公司 针头辅助喷射注射给予睾酮组合物
TWI664982B (zh) * 2012-05-09 2019-07-11 西方健康科學大學 前體脂質體睪固酮調配物
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
DK3659647T3 (da) * 2013-02-11 2024-04-22 Antares Pharma Inc Nålestøttet jetinjektionsindretning med reduceret udløserkraft
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
US12150945B2 (en) * 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
SG11202106306YA (en) * 2018-12-14 2021-07-29 Acerus Biopharma Inc Active ester derivatives of testosterone, compositions and uses thereof
WO2021067600A1 (en) * 2019-10-03 2021-04-08 Caren Pharmaceuticals, Inc. Combination hormone formulations and therapies
US20230227492A1 (en) * 2020-06-11 2023-07-20 The Usa As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods
WO2025259038A1 (en) * 2024-06-13 2025-12-18 Chong Kun Dang Pharmaceutical Corp. Injectable composition comprising tadalafil or pharmaceutically acceptable salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
PT1035835E (pt) * 1997-12-03 2003-12-31 Merck & Co Inc Formulacoes injectaveis de accao prolongada contendo oleo de ricino hidrogenado
TR200003743T2 (tr) 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
ES2222199T3 (es) 1999-04-01 2005-02-01 Akzo Nobel N.V. Preparacion que comprende testosterona undecanoato y aceite de ricino.
SI1267885T1 (sl) * 2000-02-15 2007-08-31 Bayer Schering Pharma Ag Formulacija za moško kontracepcijo, ki vsebuje noretisteron in testosteron undekanoat
AU2001291775B2 (en) * 2000-08-23 2005-09-08 N.V. Organon Testosterone ester formulation for human use

Also Published As

Publication number Publication date
HK1069325A1 (en) 2005-05-20
MXPA04002395A (es) 2004-09-20
BRPI0400214A8 (pt) 2023-05-09
WO2004080383A3 (en) 2005-03-31
HRP20050781A2 (en) 2005-10-31
SI1457208T1 (sl) 2007-02-28
ATE336251T1 (de) 2006-09-15
BRPI0400214A (pt) 2005-02-09
EP1457208A1 (en) 2004-09-15
AR043603A1 (es) 2005-08-03
EP1457208B9 (en) 2006-10-25
KR100882378B1 (ko) 2009-02-05
PE20041065A1 (es) 2005-02-24
EA200501819A1 (ru) 2006-06-30
ZA200508313B (en) 2007-04-25
RS20050702A (sr) 2007-06-04
JP4680891B2 (ja) 2011-05-11
CY1105794T1 (el) 2011-02-02
TW200511997A (en) 2005-04-01
ZA200700046B (en) 2008-04-30
UA82510C2 (uk) 2008-04-25
JO2505B1 (en) 2009-10-05
JP2006520377A (ja) 2006-09-07
EP1457208B1 (en) 2006-08-16
NO20054711D0 (no) 2005-10-13
KR20050109561A (ko) 2005-11-21
CN1761469B (zh) 2019-05-17
DE602004001893D1 (de) 2006-09-28
UY28231A1 (es) 2004-11-08
US8338395B2 (en) 2012-12-25
TWI345976B (en) 2011-08-01
PL1457208T3 (pl) 2007-01-31
HRP20050781B1 (hr) 2015-04-10
IS8069A (is) 2005-10-12
IL170473A (en) 2010-05-31
CN101884639A (zh) 2010-11-17
ME00149B (me) 2010-06-10
CL2004000527A1 (es) 2005-02-18
US20050032762A1 (en) 2005-02-10
ES2271772T3 (es) 2007-04-16
EP1743646A3 (en) 2007-03-28
BR122017008910A8 (pt) 2023-05-09
CO5700724A2 (es) 2006-11-30
CR7999A (es) 2006-05-29
NO335179B1 (no) 2014-10-13
ECSP056095A (es) 2006-03-01
AU2004218893B2 (en) 2008-10-09
AU2004218893A1 (en) 2004-09-23
RU2007118196A (ru) 2008-11-27
EA011568B1 (ru) 2009-04-28
CA2518910C (en) 2009-09-08
EP1743646A2 (en) 2007-01-17
RS51537B (sr) 2011-06-30
IS2565B (is) 2009-12-15
WO2004080383B1 (en) 2005-05-06
US20090156564A1 (en) 2009-06-18
KR20080096717A (ko) 2008-10-31
BR122017008910A2 (is) 2005-02-09
RU2005131724A (ru) 2006-05-10
DK1457208T3 (da) 2006-12-11
CA2518910A1 (en) 2004-09-23
NZ542321A (en) 2008-05-30
WO2004080383A2 (en) 2004-09-23
US7718640B2 (en) 2010-05-18
PT1457208E (pt) 2007-01-31
RU2354381C2 (ru) 2009-05-10
NO20054711L (no) 2005-12-13
CN1761469A (zh) 2006-04-19
DE602004001893T2 (de) 2007-03-15
SA04250040B1 (ar) 2008-01-07

Similar Documents

Publication Publication Date Title
MEP14508A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
DOP2009000135A (es) Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituídos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
BR0315580A (pt) Derivados de metileno uréia
BRPI0507198A (pt) derivados de bisariluréia
CU23213A3 (es) Difenilureas sustituidas con omega-carboxiarilo como inhibidores de raf quinasa
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
MX2009010989A (es) Composiciones farmaceuticas liofilizadas y metodos de obtener y usar las mismas.
AR018178A1 (es) Derivados de cromanona y tiocromanona, un proceso para su preparacion, una composicion farmaceutica que los comprende y el uso de los mismos para lapreparacion de un medicamento
TW200733980A (en) Phase transitive breath care products
NZ729628A (en) Methods for the treatment of peri-implantitis
PE20080149A1 (es) Formulacion liquida acuosa que comprende un beta bloqueador
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
BRPI0815280A2 (pt) medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
PE20090316A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias
CR10390A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion
AR038017A1 (es) Composicion anestesica acuosa y clara